Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That .95 was a small taste of what was to come. Its a top 3 at least CBD company. 25 mil is serious. All that promoting is going to really help in 2019. End of dilution from what I been seeing, uplisting, new subsidiary Diamond Hemp, New labels and bottling of professional grade. Organic products unlike CVSI. Beautiful packaging and website, almost a monopoly in Florida CBD sales. Diamond CBD owns Florida and Georgia also. Rapid expansion. CBD will be allowed in Food legally soon. DIAMONDS Liquid gold is a one of a kind product. There Cannabis terpenes oils are one of a kind. These are designer grade products that are the future. Diamond is the best name around, best products around. Revolutionary products. This stuff will be used by people on the job and at places they can't get high at, straight edge people will love it. When THC is legal they will have THC products that are superior. Q1 is going to be at least 10 million. All that marketing could have generated far more revenue than Whats expected. 13 million is not out of the question. 10-12 million is likely IMO.
Are you ready to get rich?! The tidal wave of riches is near.
Look at those revenues by the year. Looks like 44 million this year at least IMO. https://www.otcmarkets.com/stock/POTN/financials
Large Option Traders Are Selling The Aurora Cannabis Earnings Pop
Today 1:15 PM ET (Benzinga)Print
Aurora Cannabis Inc (NYSE: ACB) shares traded higher by 8 percent this week after the company reported a mixed first-quarter earnings report Tuesday evening. Options traders made some big moves following Aurora’s earnings, and the largest trades suggest the Aurora rally could soon run out of steam.
The Trades
Throughout the week, Benzinga Pro subscribers received a number of options alerts related to Aurora Cannabis.
On Wednesday morning around 10:30 a.m., a trader sold 2,000 Aurora call options at a $9 strike price that expire on Dec. 20. The calls were sold at the bid price of $1.051 and represent a $315,500 bearish on Aurora shares.
The next unusually large trade came Wednesday shortly after 2:00 p.m. The trader first sold 1,261 Aurora put options at a $9 strike price that expire on June 21 at the bid price of 95 cents. A few minutes later, likely the same trader sold another 1,000 Aurora put options at a $9 strike price that expire on June 21 at the bid price of 90.1 cents. The total put sales represented a $209,895 bullish bet on Aurora.
On Thursday afternoon, another large Aurora option trade was executed. The trader sold 1,092 Aurora call options at a $7 strike price that expire on Jan. 15, 2021. The calls were sold at the bid price of $2.601 and represent a $284,029 bearish bet on Aurora’s longer-term outlook.
On Friday morning, two more Aurora option sales were processed. The trader first sold 1,000 Aurora call options at a $8 strike price that expire on July 19. The calls were sold at the bid price of $1.051. Then, the trader came back and sold 1,937 Aurora call options at a $8 strike price that expire on January 17, 2020. The calls were sold at the bid price of $1.601. Together, the two trades represented a $415,213 bearish bet against Aurora.
Why It’s Important
Due to the relatively complex nature of the options market, options traders are generally considered to be more sophisticated than the average stock trader. In addition, large options traders are often professional, wealthy individuals or institutions, either of which could have unique insight or information about a company. Even traders that stick exclusively to stocks watch the option market closely for unusual trading activity as an indicator of where the “smart money” is focusing.
Given Aurora’s earnings report sent the stock trading higher, the mostly bearish options trading may simply be a “sell-the-news” event in which traders are taking profits on the red-hot stock.
Separately, Bank of America analysts said Aurora may be “missing the boat” in the cannabis-infused beverage business, and traders may also see better cannabis opportunities elsewhere. The firm reiterated a Buy rating and $11 price target on the stock.
Unfortunately, because stock investors often use put options to hedge larger bullish stock positions, there’s no way to be 100 percent certain whether an option trade is a standalone purchase or a hedge against a stock position. Given the buys on this week individually represented less than $500,000 bets, they are unlikely to be hedges in this case.
Aurora Cannabis's stock traded around $8.80 per share at time of publication.
TD ameritrade give this a super high P/E Ratio (TTM, GAAP)
2,320.00x
I have seen 5 different articles in the last 2 weeks stating Diamond CBD is a Market leader in the CBD game. What are people waiting on?
million ask smack! Somethings about to go down!
I'll be back when the time is right. Nelson Terry and Cam will be taking multiple vacations and things will slow down for the summer. Things will get crazy come October November December I think. I have my sights set on buying if it hits 5's or 6's or less. I am taking a risk thinking I can make a good profit elsewhere while ACB drops and buys back more ACB in a couple few months. The stock market in summer feels like fishing in a lake that isn't well stocked with fish. Management already said they don't expect a deal 6 months down the road at least a month ago. That was a hint to sell in my eyes. I think the stock valuations of these companies are on the verge of correcting and will be trading 30% to 50% closer than they are now to the actual value of these companies in the near future.
They mention CGC ACB APHA in this... https://issuu.com/redant/docs/v5_final_instadosepharma_investorpr
They mention CGC ACB APHA in this... https://issuu.com/redant/docs/v5_final_instadosepharma_investorpr
They mention ACB CGC and APHA in this. https://issuu.com/redant/docs/v5_final_instadosepharma_investorpr
Good to see your back. $$POTN$$.
I am not worried about some homophobe or racist comments. This is cannabis. Cannabis smokers go where the best weed is and MedMen is that place. As long as they seell the best pot in USA, they will be fine. Nobody want crappy weed! Medman has super dank kind buds!
Coca cola and Diamond should come out with a CBD drink called Diamond Coca cola.
No problem Protocola. I was thinking . Diamond CBD needs to make a coca cola CBD oil and get coca colas approval to use its logo on the bottle. That would boost the pps I bet.
Update products please. Most shareholders don't even know about this part of Diamond. DIAMOND HEMP! Check It Out! https://www.diamondhemp.com/
https://www.diamondcbd.com/
Buy the dips.. Not many chances left for cheap shares.
how you feeling now? did you flip?
medmen is doing a fine job IMO. shedding all that excess baggage. They are getting rid of the rejects and saving money.
Aurora Cannabis Is Selling Tons of Marijuana, but Could Still Have a Rough Path to Profitability -- Barrons.com
Today 11:53 AM ET (Dow Jones)Print
By Connor Smith
Aurora Cannabis thinks it is on the path to profitability, but an analyst at BMO Capital Markets isn't so sure.
The back story. Government data have shown that recreation sales in Canada haven't been ramping up as fast as investors had hoped.
Aurora Cannabis (ticker: ACB) reported fiscal third-quarter earnings Tuesday night, showing net revenue up 20% from the previous quarter. The company said it sold 9 metric tons of marijuana. but its revenue and adjusted loss were short of Wall Street's consensus estimates.
In an earnings call Wednesday morning, Aurora management had reiterated a fiscal fourth-quarter forecast that called for positive earnings before interest, taxes, depreciation, and amortization, or Ebitda.
What's new. BMO Capital Markets analyst Tamy Chen is still cautious about the company's path to profitability. She wrote in a note to clients Thursday that the latest quarter's results were in line with her expectations, but noted that the Canadian market "remains undersupplied" because of industry-wide challenges.
"The potential for material growth in industry recreational sales beyond existing distribution channels remains unclear over the near term given the limited roll-out of retail stores," she wrote.
Looking Ahead. Chen noted that Aurora expects to produce 25 metric tons of marijuana in the fourth quarter, but a sizable portion of that will be stockpiled for "value-added products." She expects total volume sold of 17 metric tons, which would be an 80% increase from the third quarter.
Chen has a Market Weight rating on the stock.
Aurora shares were up 0.9% to $8.76 late Thursday morning. The S&P 500 index was up 1.3%.
Barron's has taken a cautious approach to marijuana stocks and doesn't think there are bargains among pot stocks.
(END) Dow Jones Newswires
May 16, 2019 11:53 ET (15:53 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
MedMen double-diamond-bottom-pot-play-US-leader!...The dispensaries look like Apple stores, they have the real deal super dank, its high-end quality and clientele which is what Cannabis is all about. They are the biggest name in USA Cannabis. The Ceo is the kind of guy people want to make deals with. Cron's Ceo same thing. Cam and Terry are not Pot guys. It might be why cron was picked over Altria. Nerd factor in a cool dude sector.
Thanks for the kind words. I'll still be posting a bit. It could go either way. 5$ or $11, Even if I do miss ACBs big run. I have a few others with possibly far bigger upside because the price is far lower than ACB. POTN i think is going to make average joes super rich for sure. If THC is federally illegal for a couple more years. I see potn trading at least a dollar or 2 minimum. Which is the same as acb going to like 90-180 bucks per share from current prices. I think every cannabis investor should own at least a couple of the stocks ACB CGC POTN MEDMEN HArvest health CannTrust Nugs CBDS. GNCP might be making millionaires. Something extraordinary might be released involving gold assets mined over the last 7 years. Talking gold divie paying out 3 to 5 cents maybe a share people are talking. It's a lottery play but I would have at least some in it. .0003 a share. May 20th should have Fins released. I made off on ACB pretty good. I am looking for more upside in the near future than just 30%. POTN and Medmen I see giving me 50 to 300 % gains within 3 months POTN about to go crazy I feel Medmen could double quick. USA pot stocks are going to heat up again soon. As The Cannabis supply chain gets larger. I think company valuations will be closer on par with the company's actual value with all the competition.
Last year ACB dropped from 12s to 4s. and 12's to 5's. Once before legalization, and once after legalization. Sell in May and go away is so true. I am personally tired from the PR's and numbers crunching every day, I need a long vacation just like so many other traders do by the time summer rolls around. ACB will be huge. But I do think it will see 5's again. I don't think it will hit the 11 or 12 mark again till fall. See new all-time highs in December. ACB is great, but the greed of the Market is greater. I know it has a price target of 11.13. But I just don't see it. They already said they don't expect a deal until at least 6 months in an article last month. They are not looking for a huge partner but various smaller ones. I see one more massive dip before the fireworks in ACB's future. IMO. I just hate seeing my account lose a bunch waiting for the fireworks.
Let the post earning drop begin just like every time acb does it. See you at 5$ in early August.
Thanks. Hoping for tggi news.
Aurora Cannabis Inc. shares weighed on the broader cannabis sector Wednesday, after the company's fiscal third-quarter results showed losses growing at a faster-than-expected clip.
Aurora Cannabis Inc. (ACB) Ind: 7.25-8.25 Last 8.38
Today 9:17 AM ET (Dow Jones)Print
(END) Dow Jones Newswires
May 15, 2019 09:17 ET (13:17 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Aurora Cannabis's Q3 Results Miss Wall Street Targets > ACB
5/14/19 7:36 PM ET (Dow Jones)Print
Aurora Cannabis's Q3 Results Miss Wall Street Targets > ACB
By Maria Armental
Aurora Cannabis Inc.'s third-quarter results missed Wall Street targets, but the Canadian cannabis company said it remains on track for a key earnings metric to turn positive this quarter.
Third-quarter loss widened to 158.4 million Canadian dollars, or 16 Canadian cents a share, from C$19.2 million, or 4 Canadian cents a share, a year earlier.
Meanwhile, net revenue surged to C$65.1 million, a fourfold increase from a year earlier and 20% increase from the $16.1 million it reported in the second quarter.
Analysts surveyed by FactSet, however, expected a loss of C$57.6 million and C$67.5 million in sales.
The average selling price per gram fell to C$6.40, while the cash cost per gram fell to C$1.42.
Active registered patients rose to 77,136, up 5% from the previous quarter.
Aurora has brought on activist investor Nelson Peltz as a strategic adviser and has been ramping up production in Canada and expanding internationally, including exports to Australia, Luxembourg, Mexico and the U.K.
It expects to report positive earnings before interest, tax, depreciation and amortization beginning this quarter.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
May 14, 2019 19:36 ET (23:36 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
DJ Aurora Cannabis's Q3 Results Miss Wall Street Targets > ACB
By Maria Armental
Aurora Cannabis Inc.'s third-quarter results missed Wall Street targets, but the Canadian cannabis company said it remains on track for a key earnings metric to turn positive this quarter.
Third-quarter loss widened to 158.4 million Canadian dollars, or 16 Canadian cents a share, from C$19.2 million, or 4 Canadian cents a share, a year earlier.
Meanwhile, net revenue surged to C$65.1 million, a fourfold increase from a year earlier and 20% increase from the $16.1 million it reported in the second quarter.
Analysts surveyed by FactSet, however, expected a loss of C$57.6 million and C$67.5 million in sales.
The average selling price per gram fell to C$6.40, while the cash cost per gram fell to C$1.42.
Active registered patients rose to 77,136, up 5% from the previous quarter.
Aurora has brought on activist investor Nelson Peltz as a strategic adviser and has been ramping up production in Canada and expanding internationally, including exports to Australia, Luxembourg, Mexico and the U.K.
It expects to report positive earnings before interest, tax, depreciation and amortization beginning this quarter.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
May 14, 2019 19:36 ET (23:36 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
UPDATE: Aurora Cannabis losses growing faster than expected, shares fall
Today 6:55 AM ET (MarketWatch)
Share
Print
By Max A. Cherney
Stock falls about 2% in after-hours trading after the pot company beats on revenue but also sees a big increase in red ink
Aurora Cannabis Inc. losses both grew faster than expected in its fiscal third quarter, according to an earnings report released late Tuesday that sent shares about 2% lower in after-hours trading.
Canada-based Aurora (ACB.T) (ACB.T) reported fiscal third-quarter losses of C$160.1 million, or 16 cents a share, versus losses of C$20 million, or 4 cents a share, in the year-ago period. Aurora grew gross revenue to C$75.2 million, up from C$16.1 million in the year-ago period. After excluding excise taxes paid to the Canadian government, Aurora reported net revenue of C$65.2 million.
Analysts polled by FactSet on average expected fiscal third-quarter adjusted losses of 5 cents a share on net revenue of C$67.6 million. For the fiscal fourth quarter, analysts on average model adjusted losses of 3 cents a share and net revenue of C$119.4 million. The company said it lost C$77.6 million from operations, nearly double in what it lost in the year-ago period.
Compared with the fiscal second quarter, when the company sold its first recreation pot in Canada, net revenue grew 20%.
Aurora's appetite for convertible debentures contributed to the company's losses -- as Aurora's share price increases, the company must re-value the convertible debt that it has on its books. In the fiscal third quarter, that resulted in losses of C$101.5 million.
During the fiscal third quarter, Aurora also said it took impairment charges of C$9 million, due to changes related to "assets that support the production and sale of indoor home cultivation systems" and a decline in value of "certain" permits and licenses.
Aurora said it sold C$29.1 million of medical cannabis and C$29.6 million of recreational pot in the fiscal third quarter. Compared with the previous quarter, which was the first to include nearly three full months of legal Canadian recreational pot sales, Aurora grew recreational revenue 37%.
The company said it produced 15,590 kilograms of pot during the quarter, and sold 9,160 kilograms. Aurora said it nearly doubled its product because its new facility in Alberta started operations and its Ontario facilities expanded. The Alberta facility, called Aurora Sky, is expected to produce 25,000 kilograms by the end of the fiscal fourth quarter.
Aurora executives are expected to host a conference call to discuss the earnings report at 10:30 a.m. Eastern time Wednesday.
Aurora stock has gained 37% in the past year, as the S&P 500 index has risen 3.8%. The Horizons Marijuana Life Science ETF has gained 14% in the past year, and the ETFMG Alternative Harvest ETF (MJ) is up 8.7%.
-Max A. Cherney; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
I am not seeing any bear den Page on Ihub. Can you send the link?
https://investorshub.advfn.com/boards/hubstocks.aspx
you got a link
Someone just placed a fat order on the ask. Something about to go down?
GLUCODOWN(R) is a unique and compelling functional beverage and the first tea mix ever to be enriched with healthy soluble fiber. Glucose Health, Inc. is a publicly-traded company with the ticker symbol (OTC: GLUC). GLUCODOWN(R) is proudly manufactured in the USA.
they released another on for 2017
I am betting this goes down after earning to $5 before big Nelson Peltz news arranged deal news is announced. It was trading in the 4's in December. Look at the 6-month Chart. You can see what I'm talking about. Was reading an article 2 or 3 weeks ago a deal probably won't be made until at least 6 months Cam or Terry said. Probably not the huge deal like CRON and CGC had.
dowsnt seem like anybody has anything good to say about fins.
We do not expect to pay dividends for the foreseeable future.
For the foreseeable future, it is anticipated that earnings, if any, that may be generated from our operations
will be used to finance our operations and that cash dividends will not be paid to holders of our common
stock.
going up to .25 any day. Oh yeah!
Illinois has an incredible amount of Cannabis Fiends in desperate need of MedMen grade weed.